Riskpilot← Back to searchSign inGet full accessSTAVANGER UROLOGISKE SENTER AS
ASActiveOrg 998396522Hinnasvingene 55, 3. Etasje, 4020 StavangerMedical specialists activities · NACE 8622Est. 20129 employees
Revenue 2020
NOK 11,4M
+3% vs 2019
EBITDA margin
46.0%
-1% vs 2019
Equity ratio
58.4%
Financial strength
Net profit 2020
NOK 4,7M
-11% vs 2019
| Revenue | NOK 11,4M | +3% |
| EBITDA | NOK 5,3M | -1% |
| Net profit | NOK 4,7M | -11% |
| Total assets | NOK 11,7M | +13% |
| Equity | NOK 6,9M | +13% |
| Employees | 9 | — |
Legal name
STAVANGER UROLOGISKE SENTER AS
Org number
998396522
Legal form
Aksjeselskap
NACE code
8622 · Medical specialists activities
Founded
5. juni 2012
Share capital
NOK 10 000 000
Employees
9 (FTE)
VAT registered
No
Audit selected
No
Last report
2020-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Utføre spesialiserte legetjenester innen fagområdene urologi og generell kirurgi, samt lege- og konsulenttjenester som naturlig faller sammen med dette.
Address
Hinnasvingene 55, 3. Etasje, 4020 Stavanger
Phone
+4751291890
Email
post@stavangerurologiske.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|
| Revenue | 11 688 | 11 137 | 10 610 | 11 144 | 11 433 |
| Staff expenses | −3 452 | −3 210 | −3 226 | −3 379 | −3 668 |
| EBITDA | 4 212 | 4 423 | 4 652 | 5 333 | 5 255 |
| Depreciation & amort. | −516 | −240 | −230 | −220 | −132 |
| EBIT | 3 696 | 4 182 | 4 422 | 5 112 | 5 123 |
| Net financials | 17 | 252 | −318 | 1 310 | 710 |
| Profit before tax | 3 713 | 4 434 | 4 103 | 6 422 | 5 833 |
| Tax | 948 | 1 040 | 1 021 | 1 126 | 1 120 |
| Net profit | 2 765 | 3 395 | 3 082 | 5 297 | 4 713 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|
| Total assets | 5 018 | 6 295 | 8 438 | 10 373 | 11 741 |
| Equity | 1 165 | 3 660 | 5 843 | 6 039 | 6 852 |
| Long-term debt | 342 | 0 | 0 | 0 | 0 |
| Short-term debt | 3 511 | 2 635 | 2 595 | 4 334 | 4 888 |
| Total debt | 3 853 | 2 635 | 2 595 | 4 334 | 4 888 |
EBITDA margin
46.0%
This company
15.8%
Market median
+191% vs market
20162020
Equity ratio
58.4%
This company
38.2%
Market median
+53% vs market
20162020
Return on equity
68.8%
This company
18.4%
Market median
+274% vs market
20162020
Net profit margin
41.2%
This company
8.1%
Market median
+409% vs market
20162020
Asset turnover
0.97×
This company
1.12×
Market median
+13% vs market
20162020
Debt / equity
0.71×
This company
0.62×
Market median
+15% vs market
20162020
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
MS Deputy Member | Deputy Member | 2012 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
TB | Chairman | 2012 |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of STAVANGER UROLOGISKE SENTER AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Marit Selstad Alm Bru | Deputy Member | 0 companies |
| Tore Bru | Chairman | 0 companies |